331 related articles for article (PubMed ID: 21912640)
1. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma.
Zeng Z; Shi F; Zhou L; Zhang MN; Chen Y; Chang XJ; Lu YY; Bai WL; Qu JH; Wang CP; Wang H; Lou M; Wang FS; Lv JY; Yang YP
PLoS One; 2011; 6(9):e23621. PubMed ID: 21912640
[TBL] [Abstract][Full Text] [Related]
2. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
3. Association of PD-L1 gene polymorphisms and circulating sPD-L1 levels with HBV infection susceptibility and related liver disease progression.
Xuan Hoan N; Thi Minh Huyen P; Dinh Tung B; Phuong Giang D; Tat Trung N; Tien Sy B; Thi Tuan N; Thi Ngoc Dung D; Reddy Pallerla S; Velavan TP; Hong Bang M; Huu Song L
Gene; 2022 Jan; 806():145935. PubMed ID: 34478821
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
Feun LG; Li YY; Wu C; Wangpaichitr M; Jones PD; Richman SP; Madrazo B; Kwon D; Garcia-Buitrago M; Martin P; Hosein PJ; Savaraj N
Cancer; 2019 Oct; 125(20):3603-3614. PubMed ID: 31251403
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.
Umemoto Y; Okano S; Matsumoto Y; Nakagawara H; Matono R; Yoshiya S; Yamashita Y; Yoshizumi T; Ikegami T; Soejima Y; Harada M; Aishima S; Oda Y; Shirabe K; Maehara Y
J Gastroenterol; 2015 Jan; 50(1):65-75. PubMed ID: 24509608
[TBL] [Abstract][Full Text] [Related]
6. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
[TBL] [Abstract][Full Text] [Related]
7. Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance.
Long J; Qu T; Pan XF; Tang X; Wan HH; Qiu P; Xu YH
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1188-S1192. PubMed ID: 30539869
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels.
Sideras K; de Man RA; Harrington SM; Polak WG; Zhou G; Schutz HM; Pedroza-Gonzalez A; Biermann K; Mancham S; Hansen BE; Bart Takkenberg R; van Vuuren AJ; Pan Q; Ijzermans JNM; Sleijfer S; Sprengers D; Dong H; Kwekkeboom J; Bruno MJ
Sci Rep; 2019 Jul; 9(1):10677. PubMed ID: 31337865
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
[TBL] [Abstract][Full Text] [Related]
10. Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?
Sun DW; An L; Huang HY; Sun XD; Lv GY
Clin Transl Oncol; 2021 Jan; 23(1):82-91. PubMed ID: 32462395
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Dynamics of Programmed Death Ligand-1 Expression on Circulating CD14
Huang ZY; Xu P; Li JH; Zeng CH; Song HF; Chen H; Zhu YB; Song YY; Lu HL; Shen CP; Zhang XG; Wu MY; Wang XF
Viral Immunol; 2017 Apr; 30(3):224-231. PubMed ID: 28005469
[TBL] [Abstract][Full Text] [Related]
12. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma.
Wang BJ; Bao JJ; Wang JZ; Wang Y; Jiang M; Xing MY; Zhang WG; Qi JY; Roggendorf M; Lu MJ; Yang DL
World J Gastroenterol; 2011 Jul; 17(28):3322-9. PubMed ID: 21876620
[TBL] [Abstract][Full Text] [Related]
13. Regulatory T cells are associated with post-cryoablation prognosis in patients with hepatitis B virus-related hepatocellular carcinoma.
Zhou L; Fu JL; Lu YY; Fu BY; Wang CP; An LJ; Wang XZ; Zeng Z; Zhou CB; Yang YP; Wang FS
J Gastroenterol; 2010 Sep; 45(9):968-78. PubMed ID: 20411280
[TBL] [Abstract][Full Text] [Related]
14. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
15. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
[TBL] [Abstract][Full Text] [Related]
16. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
17. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation.
Itoh S; Yoshizumi T; Yugawa K; Imai D; Yoshiya S; Takeishi K; Toshima T; Harada N; Ikegami T; Soejima Y; Kohashi K; Oda Y; Mori M
Hepatology; 2020 Dec; 72(6):1987-1999. PubMed ID: 32112577
[TBL] [Abstract][Full Text] [Related]
18. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
[TBL] [Abstract][Full Text] [Related]
19. PD-1
Liu X; Li M; Wang X; Dang Z; Jiang Y; Wang X; Kong Y; Yang Z
Cancer Immunol Immunother; 2019 Dec; 68(12):2041-2054. PubMed ID: 31720814
[TBL] [Abstract][Full Text] [Related]
20. Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection.
Li N; Zhou Z; Li F; Sang J; Han Q; Lv Y; Zhao W; Li C; Liu Z
Oncotarget; 2017 Jul; 8(28):46020-46033. PubMed ID: 28545019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]